Quick Links

Breadcrumbs Navigation

Home > Clinical Trials > Adult Clinical Trials - Lymphomas - Non-Hodgkin's lymphoma and Hodgkin's disease

Jumbo Large Regular Text:

Adult Clinical Trials - Lymphomas - Non-Hodgkin's lymphoma and Hodgkin's disease

If you need additional information about any of the trials listed or would like to inquire about other open trials, please contact Peggy Alton, RN at 919-681-4769.

Items 1 - 7 of 7

Phase I/II Study of the Combination of Bendamustine, Rituximab and Pixantrone in Patients with Relapsed/Refractory B cell Non-Hodgkin's Lymphoma
Principal Investigator: Anne Beaven
Phase: Phase I
Phone: 919-681-4769

A Multicenter, Open Label, Phase II Study of Bendamustine and Rituximab followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe Study)
Principal Investigator: Anne Beaven
Phase: Phase II
Phone: 919-681-4769

A Phase 2 Study to Evaluate the Efficacy of Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Principal Investigator: Anne Beaven
Phase: Phase II
Phone: 919-681-4769

A Phase II Study Evaluating Combined Zevalin (ibritumomab tiuxetan) and Velcade (bortezomib) in Relapsed/Refractory Mantle Cell Lymphoma
Principal Investigator: Anne Beaven
Phase: Phase II
Phone: 919-681-4769

A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
Principal Investigator: Anne Beaven
Phase: Phase III
Phone: 919-681-4769

Phase II study of Dose-Reduced Consolidation Radiation Therapy in Patients with Diffuse Large B-cell Lymphoma
Principal Investigator: Christopher Kelsey
Phase: N/A
Phone: 919-668-3726

Phase IV Randomized Study of Two Dose Levels of Targretin Capsules in Patients with Refractory Cutaneous T-Cell Lymphoma
Principal Investigator: Elise Olsen
Phase: Phase IV